Congenital CMV

Clinical trials for Congenital CMV explained in plain language.

Never miss a new study

Get alerted when new Congenital CMV trials appear

Sign up with your email to follow new studies for Congenital CMV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Can an antiviral drug protect hearing in infants with congenital CMV?

Disease control Stopped early

This trial tests whether the antiviral drug valganciclovir can improve hearing and language outcomes in infants who have hearing loss due to congenital cytomegalovirus (CMV) infection. Infants aged 1 to 12 months with confirmed sensorineural hearing loss will receive either valga…

Matched conditions: CONGENITAL CMV

Phase 2 • Sponsor: Albert Park • Aim: Disease control

Last updated Aug 29, 2026 00:00 UTC

Congenital CMV

Get alerted when new Congenital CMV trials appear

Can an antiviral drug protect hearing in infants with congenital CMV?